Latest Options News

Minbos Resources has revised the timetable for its Share Purchase Plan, pushing back the opening date to 29 December 2025 and extending the closing date to early February 2026. The company confirms no new material information affects the original offer details.

MEC Resources Limited reminds eligible shareholders to participate in its Options Placement Offer closing on 20 January 2026, presenting a low-cost chance to increase exposure to its energy projects. Directors have already committed to their full entitlements, signaling confidence in the company’s direction.

Omnia Metals Group has finalized its $1.58 million placement with the issue of 25 million shares and over 70 million options, setting the stage for renewed exploration and strategic growth.

Truscott Mining Corporation has successfully raised $1.44 million through a placement, issuing 27 million new securities, and plans to kick off drilling activities early next year.

Comms Group Limited has finalized a new three-year debt refinancing agreement with Westpac, improving its financial flexibility and positioning for future acquisitions.

JAYRIDE Group has amended its quarterly cash flow report to correct classification errors, while outlining plans for a new SaaS platform rollout and potential capital raising to support operations.

Ovanti Limited has raised $3 million through a discounted share placement to fund its expansion into the US buy now, pay later market and support ongoing litigation.

Skylark Minerals has completed its acquisition of Ricca Resources’ gold assets in Côte d’Ivoire, including the advanced Zaranou Project with a JORC-compliant inferred resource of 364,600 ounces. The company is poised to begin exploration activities in early 2026.

Native Mineral Resources Holdings has locked in a $3 million convertible note raising from Lind Global Fund III LP, with the option to access up to $10 million. The funding aims to bolster working capital and support growth in the Charters Tower region.

Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.

Ventia Services Group has secured a significant $100 million contract to provide Whole-of-Government cleaning services across Western Sydney, reinforcing its long-term partnership with the NSW Government and commitment to local economic growth.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.